Chronic Kidney Disease Pathway Document Description Presented ...

More documents

Recommendations

Info

Screening and Management for People with Diabetes Annual urine analysis: Protein or Albumin Creatinine Ratio + U&Es and eGFR Follow urology/ nephrology guidelines. Does patient have persistent haematuria YES NO Does patient have proteinuria YES Present on repeat test >2 weeks later NO Does patient have eGFR
References Audit Commission (2002) Testing Times: A Review of Diabetes Services in England and Wales. Burrows-Hudson (2005) Chronic Kidney Disease: an overview. American Journal of Nursing. DOH (2001) National Standard Framework for Diabetes: Standards. The Stationary Office. London Gross J.L., de Azevedo MJ, Silveiro S.P., Canani L.H., Caramori M.L., Zelmanovitz T. (2005) Diabetic Nephropathy: Diagnosis, Prevention, and Treatment. Diabetes Care. 28, 1l 164-176. Levy J., Pussey C., Singh A. (2006) Fast Fact: Renal Disorders. Health Press, Oxford University Hospitals of Leicester NHS Trust (2006) Return to overview 47
Page 1 and 2: Chronic Kidney Disease Pathway Docu
Page 3 and 4: Pathway for the Identification and
Page 5 and 6: Contents Introduction …………
Page 7 and 8: Introduction Chronic kidney disease
Page 9 and 10: CKD Pathway D I A G N O S I S Ensur
Page 11 and 12: Kidney function deteriorates natura
Page 13 and 14: Joint Speciality Committee - Royal
Page 15 and 16: Acute Renal Failure Acute Renal Fai
Page 17 and 18: Next Steps Any patient suspected to
Page 19 and 20: Return to overview CKD Stages CKD S
Page 21 and 22: Practice Action Plan Compiling a Ch
Page 23 and 24: Action Rationale Responsible Run a
Page 25 and 26: eGFR
Page 27 and 28: CKD Stages CKD Stage Description Re
Page 29 and 30: References Joint Speciality Committ
Page 31 and 32: Cardiovascular Risk All patients wi
Page 33 and 34: Hypertension Blood pressure should
Page 35 and 36: Further information on the pharmaco
Page 37 and 38: Irbesartan* Valsartan Losartan* *Sp
Page 39 and 40: • Diuretics • Lithium carbonate
Page 41 and 42: Recommendation: Therefore consider
Page 43 and 44: Lower levels of proteinuria should
Page 45: Glycaemic Control CKD and Diabetes
Page 49 and 50: Influenza and Pneumococcal Vaccine
Page 51 and 52: Stage 3 Management at stage 3 shoul
Page 53 and 54: If all other causes for the anaemia
Page 55 and 56: Clinic inclusion criteria: Patients
Page 57 and 58: Where vitamin D supplementation is
Page 59 and 60: Stage 5 Patients identified at CKD
Page 61 and 62: Information to include with referra
Page 63 and 64: Appendix 1 The Dudley Group of Hosp

Chronic Kidney Disease Pathway Document Description Presented ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?